/
FATE
$2.42+$0.32 (+15.24%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$244.8M
117M shares
52-week range
$0.91 – $2.88
77% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-91.87
Fate Therapeutics, Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
www.fatetherapeutics.com- Employees
- 161
- IPO / List date
- Oct 1, 2013
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds FATE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,974,683 | $3.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FATE yet.
